ALT5 Sigma Corporation (NASDAQ: ALTS) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. Since June of 2025, the Company has been a member of the Russell Microcap Growth®, Russell 3000E®, and Russell 3000E Growth®Indexes, as part of the 2025 Russell indexes reconstitution. The Company had previously been included in the Russell Microcap® Index since June of 2024.
Founded in 2018, ALT5 Sigma, Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) enables the migration to a new global financial paradigm through its suite of blockchain infrastructure technologies. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms: “ALT5 Pay” and “ALT5 Prime.” The company has processed over $5 billion USD in cryptocurrency transactions since inception.
ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.
ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.
The Company is also advancing the separation of its biotech business, which will continue under “Alyea Therapeutics Corporation.” Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.